Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)

Kidney International Reports

Volumn 4, Issue 11, 2019, Pages 1633-1637

  Barratt, Jonathan ^a   Rovin, Brad ^b   Diva, Ulysses ^c   Mercer, Alex ^d   Komers, Radko ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c Retrophin Inc   (United States)

^d PharmaLogic Consulting AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IRBESARTAN; PLACEBO; SPARSENTAN;

ARTICLE; CREATININE BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA;

EID: 85073256969     PISSN: 24680249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ekir.2019.08.007     Document Type: Article

References (5)

1. Inker LA, Heerspink HL. Evaluation of surrogate end points for progression to ESKD: necessary and challenging. Am J Kidney Dis. 2018;72:771-773.
2. Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128-139.
3. Thompson A, Carroll K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14:469-481.
4. Wanner C, Heerspink HJL, Zinman B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. 2018;29:2755-2769.
5. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930-1942.